U

    Unicycive Therapeutics Inc (UNCY)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.20
    -0.07 (-1.23%)

    Market Cap: $144.22M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    43%(9/21)
    Avg Surprise
    -12.63%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.31
    Range$-0.40 - $-0.23
    8 analysts
    EPS Revisions
    2
    0
    7d
    2
    1
    30d
    EPS Estimate Drift
    90d ago$0.15+148.5%
    60d ago$0.16+152.4%
    30d ago$-0.34-8.3%
    7d ago$-0.33-5.9%
    Current$-0.31
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    Dec 31, 2026
    EPS Consensus$-0.09
    Range$-0.33 - $0.49
    7 analysts
    Revenue Consensus
    $275380
    Range$0 - $2M
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.09---
    Sep 26EST
    		-$-0.31---
    Jun 26
    		$-0.06N/A+82.35%Beat+88.5%
    Mar 26
    		$-0.54$-0.47-13.62%Miss-7.3%
    Dec 25
    		$-0.82$-0.46-78.26%Miss-428.0%
    Sep 25
    		$-0.33$-0.53+37.74%Beat+34.0%
    Jun 25
    		$-0.52$-0.70+25.71%Beat-134.7%
    Mar 25
    		$-0.50$-0.62+19.35%Beat+91.8%
    Dec 24
    		$0.25$-0.09+373.52%Beat+213.6%
    Sep 24
    		$-0.50N/A+67.11%Beat+61.5%
    Jun 24
    		$1.50$-1.92+178.13%Beat+151.7%
    Mar 24
    		$-6.10$-1.55-293.55%Miss+37.1%
    Dec 23
    		$-0.22$-0.17-29.41%Miss+37.1%
    Sep 23
    		$-1.30$-1.30+0.00%Beat+64.9%
    Jun 23
    		$-2.90$-3.20+9.38%Beat-20.8%
    Mar 23
    		$-9.70$-3.72-160.75%Miss-304.2%
    Dec 22
    		$-0.35$-0.24-45.83%Miss-45.8%
    Sep 22
    		$-3.70$-2.80-32.14%Miss+0.0%
    Jun 22
    		$-2.40$-2.27-5.73%Miss-84.6%
    Mar 22
    		$-2.40$-1.90-26.32%Miss-3328.6%
    Dec 21
    		$-0.24$-0.13-84.62%Miss-300.0%
    Sep 21
    		$-3.70$-1.00-270.00%Miss-12233.3%
    Jun 21
    		$-1.30$-1.10-18.18%Miss-
    Mar 21
    		$-0.07$0.00N/AMiss-
    Sep 20
    		$-0.06$0.00N/AMiss-
    Jun 20
    		$-0.03$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-2.98EV/EBITDA-1.03x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-101.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio3.81xQuick Ratio3.81x
    Trading Statistics
    Beta1.78Avg Volume720.03K
    52-Week High$8.7452-Week Low$3.71

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.45
    SMA 20$5.35
    SMA 50$5.59
    SMA 200$6.43
    EMA 10$5.38
    EMA 20$5.39
    EMA 50$5.68
    EMA 200$6.14

    MACD

    Line: -0.04Signal: -0.05Hist: 0.01

    ADX

    ADX: 11.7+DI: 20.5-DI: 25.7

    Aroon & PSAR

    Aroon Up64.0
    Aroon Down8.0
    PSAR$4.86

    Bollinger Bands

    Upper Band$5.76
    Lower Band$4.93
    %B Position1552%(Upper)
    Band Width0.32

    RSI (14-Day)

    Neutral
    44.2

    Momentum Oscillators

    Stoch %K38.4
    Stoch %D49.2
    Williams %R-80.5
    ROC (10d)-6.6%
    Momentum-0.37
    CCI (20d)-66.3
    MFI (14d)59.4

    Volatility Measures

    ATR (14d)$0.29(5.6%)
    StdDev (20d)0.21
    Hist Vol45.8%(High)

    Volume Flow

    VWAP$5.19
    OBV-31.4M
    AD Line26.2B
    CMF (20d)-0.129

    Volume Metrics

    Avg Vol (20d)726.6K
    Vol Ratio0.8x
    VWMA (20d)$5.36

    Pivot Points

    R3$5.66
    R2$5.58
    R1$5.42
    Pivot Point$5.34
    S1$5.18
    S2$5.10
    S3$4.94

    Advanced Oscillators

    TSI-3.38
    Ultimate Osc42.9
    KST38.61

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$568,000$0$0$0$-271,000$0
    Cost of Revenue$0$0$151,000$0$0$0$284,000$0$0$0$82,000$0
    Gross Profit$0$0$-151,000$0$0$0$284,000$0$0$0$-353,000$0
    Operating Expenses$10.14M$8.44M$7.22M$7.34M$6.96M$7.99M$9.26M$6.25M$7.40M$9.20M$6.31M$5.94M
    R&D$2.79M$1.61M$2.24M$2.96M$1.75M$2.17M$5.29M$3.04M$4.87M$6.81M$4.23M$3.37M
    SG&A$7.35M$6.83M$4.99M$4.38M$5.21M$5.82M$3.97M$3.21M$2.53M$2.39M$2.08M$2.57M
    Operating Income$-10,140,000$-8,437,000$-7,223,000$-7,342,000$-6,963,000$-7,989,000$-9,261,000$-6,251,000$-7,401,000$-9,204,000$-6,312,000$-5,938,000
    Interest Income$441,000$394,000$352,000$279,000$155,000$226,000$314,000$416,000$462,000$69,000$140,000$227,000
    Interest Expense$0$0$28,000$15,000$13,000$15,000$20,000$15,000$16,000$20,000$20,000$18,000
    Income Before Tax$-1,722,000$-12,823,000$-14,667,000$-6,011,000$-6,447,000$570,000$-21,525,000$-4,096,000$9.86M$-20,963,000$-7,798,000$-4,333,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-1,722,000$-12,823,000$-14,667,000$-6,011,000$-6,447,000$570,000$-21,525,000$-4,096,000$9.86M$-20,963,000$-7,798,000$-4,333,000
    EBITDA$-2,045,000$-12,994,000$-14,840,000$-6,265,000$-6,451,000$494,000$-21,812,000$-4,491,000$9.30M$-20,728,000$-7,915,000$-4,540,000
    EBIT$-2,163,000$-13,217,000$-14,991,000$-6,275,000$-6,589,000$359,000$-21,819,000$-4,497,000$9.41M$-21,012,000$-7,918,000$-4,542,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about UNCY

    News

    UNCY Should I Buy

    Unicycive Therapeutics Inc (UNCY) is considered a good buy due to its current price being significantly lower than analyst targets, and it has shown strong long-term growth potential with a 31.24% increase over the past year. However, it faces risks from a recent FDA Complete Response Letter causing a stock price drop due to manufacturing issues. Analysts maintain "Buy" ratings, anticipating a potential New Drug Application resubmission by year-end 2026, while the company has a cash balance sufficient until 2027.

    Intellectia AI•8/23/26•
    Somewhat-Bullish

    Unicycive Therapeutics (NASDAQ:UNCY) Upgraded at Zacks Research

    Zacks Research has upgraded Unicycive Therapeutics (NASDAQ:UNCY) from a "strong sell" to a "hold" rating. Despite the upgrade, the stock opened at $5.45, below its moving averages, and has a "Moderate Buy" consensus rating with an average price target of $18.75. The company recently reported a quarterly loss of $0.06 per share, outperforming analyst estimates, and institutional ownership stands at 40.42%.

    MarketBeat•8/21/26•
    Somewhat-Bullish

    Benchmark Co. Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Raises Target Price to $15

    Benchmark Co. has reiterated its Buy rating for Unicycive Therapeutics (UNCY.US) and increased its price target for the company's stock to $15. This suggests a positive outlook from the firm regarding UNCY's future performance.

    Moomoo•8/20/26•
    Bullish

    UNCY Maintained by Benchmark -- Price Target Raised to $15.00

    Benchmark has maintained its rating on Unicycive Therapeutics (UNCY) and raised its price target from $13.00 to $15.00, reflecting cautious optimism for the clinical-stage biotechnology company focused on kidney disease therapies. Despite the positive analyst rating, the company has a low GF Score of 34/100 due to profitability concerns, and there's a lack of recent guru or insider interest, suggesting investors should weigh these factors carefully. UNCY's high price-to-sales ratio and unprofitability also make traditional valuation challenging.

    GuruFocus•8/20/26•
    Somewhat-Bullish

    UNICYCIVE THERAPEUTICS INC : BENCHMARK RAISES TARGET PRICE TO $15 FROM $13

    Benchmark has increased its target price for UNICYCIVE THERAPEUTICS INC (UNCY.O) from $13 to $15. This update was reported by Reuters on August 20, 2026. The article notes that the content reflects the author's opinion and is not investment advice.

    Bitget•8/20/26•
    Bullish

    Frequently Asked Questions About UNCY

    Does UNCY pay dividends?
    Unicycive Therapeutics Inc (UNCY) does not currently pay a regular dividend.
    What is UNCY's market cap?
    Unicycive Therapeutics Inc (UNCY) has a market capitalization of $144.22M with a current stock price of $5.20.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In